{"id":"NCT00704028","sponsor":"American Regent, Inc.","briefTitle":"Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia","officialTitle":"A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-01","completion":"2011-03","firstPosted":"2008-06-24","resultsPosted":"2013-11-25","lastUpdate":"2018-02-20"},"enrollment":161,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose","otherNames":[]},{"type":"DRUG","name":"Iron Dextran","otherNames":["Dexferrum, INFeD"]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Iron Dextran","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.","primaryOutcome":{"measure":"The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's)","timeFrame":"Day 0 through end of study (Day 42), or 28 days after the last dose of study drug whichever was longer","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":60,"sd":null},{"arm":"Iron Dextran","deltaMin":59,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":82},"commonTop":["Nausea","Headache","Dizziness","Vomiting","Diarrhea"]}}